SG Americas Securities LLC Acquires 10,046 Shares of Accuray Incorporated (NASDAQ:ARAY)

SG Americas Securities LLC boosted its position in Accuray Incorporated (NASDAQ:ARAY) by 28.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 45,862 shares of the medical equipment provider’s stock after purchasing an additional 10,046 shares during the quarter. SG Americas Securities LLC’s holdings in Accuray were worth $130,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in ARAY. Ameritas Investment Partners Inc. bought a new stake in Accuray in the 2nd quarter valued at $30,000. Royal Bank of Canada boosted its stake in Accuray by 251.4% in the 2nd quarter. Royal Bank of Canada now owns 8,343 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 5,969 shares during the period. Commonwealth Equity Services LLC bought a new stake in Accuray in the 3rd quarter valued at $35,000. Zebra Capital Management LLC bought a new stake in Accuray in the 1st quarter valued at $37,000. Finally, Lazard Asset Management LLC bought a new stake in Accuray in the 2nd quarter valued at $40,000. 64.08% of the stock is currently owned by institutional investors.

Accuray Price Performance

Accuray stock opened at $2.19 on Thursday. The company has a debt-to-equity ratio of 3.53, a quick ratio of 0.84 and a current ratio of 1.58. Accuray Incorporated has a 52 week low of $2.17 and a 52 week high of $4.30. The stock has a market capitalization of $217.18 million, a P/E ratio of -14.60 and a beta of 1.44. The stock has a fifty day moving average of $2.56 and a 200-day moving average of $2.67.

Accuray (NASDAQ:ARAY) last posted its quarterly earnings results on Wednesday, January 31st. The medical equipment provider reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.05). Accuray had a negative return on equity of 28.11% and a negative net margin of 3.25%. The business had revenue of $107.24 million for the quarter, compared to analyst estimates of $107.11 million. During the same period last year, the firm posted ($0.02) EPS. On average, sell-side analysts expect that Accuray Incorporated will post -0.07 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ARAY. Roth Capital reaffirmed a “buy” rating on shares of Accuray in a report on Tuesday, February 13th. Roth Mkm began coverage on Accuray in a report on Tuesday, February 13th. They issued a “buy” rating and a $9.00 price objective for the company. Finally, TheStreet cut Accuray from a “c-” rating to a “d+” rating in a report on Wednesday, February 14th. One research analyst has rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $8.25.

Accuray Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.